**Summary**
Baillie Gifford Shin Nippon PLC (BGS) has published a circular outlining a tender offer for up to 15% of its issued ordinary shares, along with other proposals. The tender offer aims to allow shareholders to realize some or all of their investment in the short term, while also introducing a new 100% performance-related tender offer for 2030 to maintain a long-term performance-based approach. The company is also proposing a 2028 continuation vote to allow shareholders to decide on the companys future.
**Key Points**
1. **Tender Offer**Up to 15% of issued ordinary shares can be tendered by eligible shareholders, with a 2% discount applied to the net asset value (NAV) per share.
2. **Cancellation of 2027 Conditional Tender Offer**: The board recommends canceling this offer, as it provides insufficient time to assess the portfolio managers performance.
3. **New 2030 Performance-Related Tender Offer**: A 100% performance-related tender offer will be introduced for 2030, providing a longer-term performance-based approach.
4. **2028 Continuation Vote**Shareholders will have the opportunity to vote on the companys future in 2028.
5. **Background**Recent changes in portfolio management and investment policy have led to a review of the companys performance, with the board believing its too early to assess the impact of these changes.
6. **Shareholder Consultation**The board consulted with shareholders representing over 43% of the companys issued share capital, who expressed frustration with poor performance but recognized the unique opportunity offered by the company.
7. **Timetable**The tender offer opens on January 23, 2026, with a record date of February 26, 2026, and results announced on February 27, 2026.
8. **Notice to US Shareholders**The tender offer is subject to UK disclosure and procedural requirements, which differ from US regulations. US shareholders should consult the circular and seek tax advice.
This summary highlights the main aspects of the circular, including the tender offer, changes to performance-related offers, and shareholder consultation, while also noting the regulatory considerations for US shareholders.